Dr. Karen Reckamp, MD, MS, Co-Director of the Lung Cancer and Thoracic Oncology Program, Medical Director – Clinical Research Operations, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Reckamp discusses immunotherapy for previously treated patients with non-small cell lung cancer. Â
Please visit our forums at http://cancergrace.org/forum/q-and-a-ask-us, and scroll to the bottom of the page to ask a question!Â
Â
Please feel free to offer comments and raise questions in our Discussion Forums.
    Â
    Â
Â
Â
         Â
    Â
Â
 ÂÂ
Â
 Â
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University again joined GRACE to discuss updates to the basics of lung cancer. In this (audio only, Spanish language) webcast for the Spanish lung cancer video library, Dr. Raez discusses PDL1 as a biomarker for second-line treatment.
Â
Please feel free to offer comments and raise questions in our Discussion Forums.
TRANSCRIPTS – Spanish and English
PDL1 como biomarcador para segundo tratamiento
PDL1 as a biomarker for second-line treatment
H. Jack West, MD
President & CEO, GRACE
We are pleased to have GRACE’s Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute in Seattle, Washington, and President and CEO of GRACE bring 2017 updates to our Lung Cancer Video Library. Â
In this latest video, Dr. West discusses exciting new advances in NSCLC – Â PDL1 as a Biomarker for Second Line.
Â
Please feel free to offer comments and raise questions in our Discussion Forums.
    Â
    Â
Â
Â
         Â
    Â
Â
 ÂÂ
Â
 Â
In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival. No further details were offered at that time, but additional data were submitted to the FDA just days before the FDA approved Opdivo on March 4, 2015 and made it commercially available for these patients (with the FDA deserving credit for seemingly waiting in a conference room to go through an immediate approval process once the full data was supplied). We have since learned that Opdivo was associated with a significant, 3.2 month improvement in median overall survival, 9.2 vs. 6.0 months, but additional data await presentation at the annual ASCO meeting in Chicago in late May/early June.
Bristol-Myers-Squibb  (BMS) ran a parallel trial called CheckMate 057, also directly comparing Opdivo to docetaxel as second line therapy for patients with non-squamous NSCLC, which comprises about 75-80% of NSCLC patients in North America.  That trial completed enrollment around the same time as the squamous trial, but no results were forthcoming until this week, when a press release from BMS noted that an interim data review from this trial has demonstrated a significant survival benefit again for Opdivo — with no additional data offered yet.Â
Recent Comments